


Claim Listings:

Claims 1-5. (Cancelled).

6. (Currently Amended) **A** The compound of ~~any of claims 1-4~~ **formula I:**




wherein: R¹ is selected from OH or NH₂ and is at the ortho-position relative to heterocycle X;

R² is selected from OCH₃ and H and is at the para-position relative to heterocycle X;**and**
R³ is H;


X a is a 5 membered aromatic heterocycle that is optionally substituted with C₁-C₄ alkyl; wherein said heterocycle contains at least two or three heteroatoms selected from N, S and O wherein at least one heteroatom must be N and wherein said heterocycle may not be 1,3,4-oxadiazole; and
n is 2, 3, 4, 5, 6, or 7;
or a pharmaceutical salt thereof.

7. (Original) A compound which is:




or a pharmaceutical salt thereof.

8. (Original) A compound which is:



or a pharmaceutical salt thereof.


9. (Original) A compound which is:



or a pharmaceutical salt thereof.


- 10-11. (Canceled)

12. A compound which is:



or a pharmaceutical salt thereof.

13. A compound which is:



or a pharmaceutical salt thereof.

14. (Currently Amended) A pharmaceutical composition comprising:
a) **a the** compound of claims ~~3, 5-9 or 11-13~~ **6** or a pharmaceutical salt thereof;
and
b) a GLP-1 compound.
15. The composition of claim 14, wherein the GLP-1 compound is Val⁸-Glu²²-GLP-1(7-37)OH.
16. (Currently Amended) A pharmaceutical composition comprising:
a) **a the** compound of claims ~~3, 5-9 or 11-13~~ **6** or a pharmaceutical salt thereof;
and
b) an MC4 agonist peptide.
17. The composition of claim 16 wherein the MC4 agonist is selected from the group consisting of:
Ac-Arg-cyclo[Cys-Glu-His-D-Phe-Arg-Trp-Cys]-NH₂;
Ac-cyclo[hCys-His-D-Phe-Arg-Trp-Cys]-NH₂;
Ac-cyclo[hCys-His-D-Phe-Arg-Trp-penicillamine]-NH₂; and
N-cyclohexanecarbonyl-cyclo[hCys-His-D-Phe-Arg-Trp-penicillamine]-NH₂.